Full text is available at the source.
Clinical neurology and neurosurgery···
MGMT gene status linked to outcomes in inoperable brain cancer after additional treatment
Updated
Abstract
In a study of 55 patients with non-resectable glioblastoma, 51.2% of those biopsied had a methylated MGMT promoter.
- Methylation of the MGMT promoter is associated with improved overall survival compared to unmethylated status.
- In the biopsy group, patients with methylated MGMT had a mean overall survival of 11.4 months, while unmethylated patients had 4.8 months.
- In the resection group, methylated patients had a mean overall survival of 21.7 months, compared to 14.0 months for unmethylated patients.
- Patients with unmethylated MGMT promoter status may not benefit as much from adjuvant therapies like XRT/TMZ.
- The study suggests that unmethylated MGMT status could be a significant predictor of poor prognosis in biopsied glioblastoma patients.
Simplified
BACKGROUND: Methylation of MGMT promoter has been identified as a favourable predictive factor of benefit from XRT/TMZ → TMZ. Patients with non-resectable glioblastoma (GBM) generally exhibit a poor prognosis, even after XRT/TMZ. Few data are available concerning the predictive value of MGMT promoter methylation in this population.
METHODS: This is an observational retrospective study in patients with malignant brain glioma, treated between June 2008 and October 2011 and followed up until April 2012 at the Neurosurgery-Neurotraumatology Unit of the University Hospital of Parma and at the Neurosurgery Unit of IRCCS "ASMN" of Reggio Emilia, Italy. The medical records of an overall number of 174 patients with a newly diagnosed GBM were reviewed. Volumetry analysis of the lesions was performed on pre- and post-operative neuroimaging by Voxar 3D Ebit AET software. The genetic characterization was performed on paraffin embedded tissue from all resected tumours. Isolation of nucleic acids, bisulfite modification of DNA, methylation-specific PCR and sequencing analyses were done mainly on fresh tissue from biopsy withdrawals. Within 3-4 weeks after either biopsy or surgery, patients were assigned to receive XRT/TMZ→TMZ: treatment included XRT (60 Gy in 30 fractions)/TMZ (daily dose of 75 mg/m(2))/TMZ (150-200mg/m(2) per day for 5 days of every 28-day cycle).
RESULTS AND DISCUSSION: A total of 55 consecutive patients (23 men, 22 women) fulfilled inclusion criteria consisting of age over 18 years, supratentorial histologically proven primary malignant glioma, complete determination of the MGMT methylation status, no prior history of surgery, XRT and/or chemotherapy, adequate clinical and radiological follow-up no lesser than 6 months. Twenty-three patients underwent neuronavigation needle biopsy (B Group) and thirty-two patients were operated with craniotomy for tumour resection (R Group). The pre-operative mean age was similar between groups (61.7 ± 10.7 vs 60.3 ± 11.8 years in the B and R groups respectively; p>0.05). The B groups showed a slightly lower KPS than the R Group (82.1 ± 17.3 vs 90.3 ± 14.1 respectively; p>0.05). The mean pre-operative volume of the tumour did not differ between groups (46.2 ± 40.2 cm(3) vs 44.1 ± 33.2 cm(3) in the R Group and B Group respectively; p>0.05). The MGMT promoter was methylated in 12 patients (51.2%) of B Group and in 17 patients (53.1%) of R Group. XRT/TMZ → TMZ was accomplished in 11 patients (47.8%) of B Group and in 24 patients (75%) of R Group; in 24/29 methylated patients (82.8%) and in 11/26 unmethylated patients (42.3%). Survival analysis of methylated vs unmethylated tumours was statistically significant (Log Rank Mantel Cox: 0.019 in B Group and 0.023 in R Group). In B Group the mean overall survival (OS) of methylated patients was 11.4 months (IC 95% 6.5-16.4) vs 4.8 months (95% IC, 2.6-7.0) of unmethylated patients. In R Group the mean OS was 21.7 months (95% IC, 16.9-26.6) for methylated patients and 14.0 months (95% IC, 8.5-19.4) for unmethylated patients. At the multivariate Cox regression analysis conducted on the total population (55 patients), XRT and TMZ were found to be predictive of OS. In the R Group, KPS, XRT and TMZ correlated with a better outcome. In the B Group, XRT and MGMT promoter methylation were favourably related with OS.
CONCLUSION: MGMT promoter unmethylation has a predominant unfavourable impact on clinical outcomes even in the subpopulation of patients with non-resectable GBM. The unmethylated MGMT promoter status could be considered the main predictor of poor prognosis in biopsied GBM, due to the greater probability of patients not having benefits from adjuvant therapies and not being able to accomplish XRT/TMZ → TMZ. The frameless neuronavigation biopsy technique is safe and effective for predictive evaluation and could help in treatment decision making.
Related papers
Feb '12
MGMT gene changes and protein levels as predictors in brain tumor patients treated with carmustine wafers, radiation, and temozolomide after surgery
top 5% journal
cited by 72 papers
research support, non-u.s. gov't
Dec '14
Long-term temozolomide treatment is possible for new glioblastoma patients: experience with up to 101 treatment cycles
top 20% journal
cited by 66 papers
journal article
May '13
MGMT gene methylation and outlook for patients with first-time or returning glioblastoma treated with carmustine wafers
top 50% journal
cited by 26 papers
clinical trial, phase iii
Mar '12
MGMT gene methylation linked to outcomes in glioblastoma patients treated with temozolomide and radiation
top 5% journal
cited by 45 papers
research support, non-u.s. gov't
Feb '13
Benefits of temozolomide combined with radiotherapy in standard treatment for new glioblastoma cases
cited by 22 papers
comparative study
May '18
Comparing two tests for detecting MGMT gene changes in glioblastoma patients
top 10% journal
cited by 16 papers
journal article
Feb '15
MGMT Promoter Methylation Predicts Benefit from Higher-Dose Temozolomide Retreatments in Advanced Glioblastoma
top 1% journal
cited by 283 papers
randomized controlled trial